Skye Bioscience, Inc. Common Stock (SKYE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.83M
Last updated: Nov 17, 2026 at 11:03 AM ET
Skye Bioscience, Inc. Common Stock (SKYE) Earnings: Report Dates and Results
Skye Bioscience, Inc. Common Stock (SKYE) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Skye Bioscience, Inc. Common Stock reported EPS of -$2.56, below the -$1.12 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SKYE has an expected report date of Mar 8, 2027.
SKYE Earnings Call
The latest SKYE earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 12 quarters below that had an estimate, SKYE beat 3, missed 7 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 128.57% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$2.56 | -$1.12 | -$1.12 - -$1.12 | -128.57% | Miss | N/A | 1 | 0 up, 0 down | Nov 16, 2026 |
| Jun 30, 2026 | -$0.27 | -$0.29 | -$0.36 - -$0.14 | +6.90% | Beat | N/A | 6 | 0 up, 1 down | Aug 14, 2026 |
| Mar 31, 2026 | -$0.32 | -$0.32 | -$0.51 - -$0.18 | 0.00% | In line | N/A | 6 | 1 up, 2 down | May 11, 2026 |
| Dec 31, 2025 | -$2.95 | -$2.45 | -$2.88 - -$1.84 | -20.20% | Miss | N/A | 6 | 0 up, 0 down | Mar 10, 2026 |
| Sep 30, 2025 | -$0.32 | -$0.32 | -$0.43 - -$0.24 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Nov 10, 2025 |
| Jun 30, 2025 | -$0.44 | -$0.34 | N/A | -29.41% | Miss | N/A | 4 | 0 up, 2 down | Aug 7, 2025 |
| Mar 31, 2025 | -$0.28 | -$0.29 | -$0.31 - -$0.26 | +3.45% | Beat | N/A | 4 | 1 up, 2 down | May 8, 2025 |
| Dec 31, 2024 | -$0.29 | -$0.29 | -$0.34 - -$0.23 | -2.18% | Miss | N/A | 6 | 2 up, 0 down | Mar 20, 2025 |
| Sep 30, 2024 | -$0.10 | -$0.25 | -$0.34 - -$0.17 | +60.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2024 |
| Jun 30, 2024 | -$0.20 | -$0.19 | -$0.26 - -$0.14 | -5.26% | Miss | N/A | 4 | 0 up, 0 down | Aug 9, 2024 |
| Mar 31, 2024 | -$0.18 | -$0.16 | -$0.16 - -$0.16 | -12.50% | Miss | N/A | 1 | 0 up, 0 down | May 10, 2024 |
| Dec 31, 2023 | -$0.63 | -$0.38 | -$0.38 - -$0.38 | -65.79% | Miss | N/A | 1 | 0 up, 0 down | Mar 22, 2024 |
| Sep 30, 2023 | -$3.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2023 |
| Jun 30, 2023 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 7, 2023 |
| Mar 31, 2023 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2023 |
| Dec 31, 2022 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2023 |
| Sep 30, 2022 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2022 |
| Jun 30, 2022 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 15, 2022 |
| Mar 31, 2022 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 6, 2022 |
| Dec 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 25, 2022 |
| Sep 30, 2021 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2021 |
| Jun 30, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 6, 2021 |
| Mar 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2021 |
| Dec 31, 2020 | -$0.01 | N/A | N/A | N/A | N/A | -133.3% | N/A | N/A | Mar 1, 2021 |
| Sep 30, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 6, 2020 |
| Jun 30, 2020 | -$0.01 | N/A | N/A | N/A | N/A | -112.5% | N/A | N/A | Aug 13, 2020 |
| Mar 31, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2020 |
| Dec 31, 2019 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 20, 2020 |
| Sep 30, 2019 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2019 |
| Jun 30, 2019 | $0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2019 |
| Mar 31, 2019 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2019 |
| Dec 31, 2018 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 14, 2019 |
| Sep 30, 2018 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2018 |
| Jun 30, 2018 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2018 |
| Mar 31, 2018 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2018 |
| Dec 31, 2017 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 19, 2018 |
| Sep 30, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 |
| Jun 30, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2017 |
| Mar 31, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2017 |
| Dec 31, 2016 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 10, 2017 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.99, after -$0.77 the year before. It was -$37.68 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.99 | N/A |
| Dec 31, 2024 | -$0.77 | N/A |
| Dec 31, 2023 | -$3.80 | N/A |
| Dec 31, 2022 | -$0.04 | N/A |
| Dec 31, 2021 | -$0.03 | N/A |
| Dec 31, 2020 | -$0.04 | N/A |
| Dec 31, 2019 | -$0.04 | N/A |
| Dec 31, 2018 | -$0.18 | N/A |
| Dec 31, 2017 | -$0.09 | N/A |
| Dec 31, 2016 | -$37.68 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 7,200 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 7,182 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,133 | 11 | |
| 2025Q1 | Mar 31, 2025 | 5,818 | 14 | |
| 2024Q4 | Dec 31, 2024 | 7,680 | 14 | |
| 2024Q3 | Sep 30, 2024 | 6,146 | 12 |
2025Q3 Earnings Call
Opening remarks
Bernie Hertel Head of Investor Relations Hello, and thank you all for participating in today's call. Before we begin, I'd like to caution that comments made during this conference call will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements of Skye Bioscience, Inc.'s expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statements made today. I encourage you to review all of the company's filings with the Securities and Exchange concerning these and other matters. I'll now turn the call over to Kaitlyn Arsenault, Skye's CFO.
Kaitlyn Arsenault CFO Thanks, Bernie. After the market closed today, we issued a release and filed Skye Bioscience, Inc.'s Form 10-Q with the Securities and Exchange Commission, outlining our quarterly financial results. We encourage you to reference our filings for the details of our financials and the risk factors described therein. I will now provide a brief overview of our key financial results for the third quarter ended September 30, 2025. We ended the third quarter with cash and cash equivalents and short-term investments totaling $35.3 million. We expect our current working capital to fund operations and key clinical milestones into 2027. This includes the completion of the extension of our Phase 2a study for Nimazumab, certain manufacturing, and preparatory clinical activities needed to initiate the next study. In addition, our runway continues to include a modest discovery R&D budget, the dose concentration, and process intensification work required to support our expected TPP and scale and support later-stage studies for Nimazumab. R&D expenses for the three months ended September 30, 2025, were $9.4 million as compared to $4.9 million for the same period in 2024. The increase was primarily due to contract manufacturing, clinical trial costs associated with our obesity study for Nolasimab, discovery R&D expenses, salary and stock-based compensation expense, and consulting, advisory, and professional fees. General and administrative expenses for the three months ended September 30, 2025, were $3.9 million as compared to $4.6 million for the same period in 2024. The decrease was primarily related to decreases in consulting, advisory, and professional fees, recruitment fees, salaries, and stock-based compensation expense. Our net loss for the three months ended September 30, 2025, totaled $12.8 million, including non-cash share-based compensation expense of $1.9 million, compared to $3.9 million for the same period in 2024 with non-cash share-based compensation expense of $1.9 million.
Frequently Asked Questions About SKYE
When is Skye Bioscience, Inc. Common Stock's next earnings date?
Skye Bioscience, Inc. Common Stock's next earnings report is expected for Mar 8, 2027.
Did SKYE beat earnings estimates last quarter?
No. Skye Bioscience, Inc. Common Stock reported EPS of -$2.56 for the quarter ended Sep 30, 2026, below the -$1.12 estimate by 128.57%.
What EPS do analysts expect from SKYE next quarter?
The consensus EPS estimate for Skye Bioscience, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.09 from 5 analysts, with estimates from -$1.18 to -$0.92.
How often does SKYE beat earnings estimates?
Skye Bioscience, Inc. Common Stock beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -21.25%.
SKYE pages: Overview, Earnings, Forecast, Financials, Competitors